HK1256839A1 - 临床制剂 - Google Patents

临床制剂 Download PDF

Info

Publication number
HK1256839A1
HK1256839A1 HK18115924.9A HK18115924A HK1256839A1 HK 1256839 A1 HK1256839 A1 HK 1256839A1 HK 18115924 A HK18115924 A HK 18115924A HK 1256839 A1 HK1256839 A1 HK 1256839A1
Authority
HK
Hong Kong
Prior art keywords
clinical
tissue
preparations
cell
media
Prior art date
Application number
HK18115924.9A
Other languages
English (en)
Chinese (zh)
Inventor
Gay Roger
RATLIFF Judson
E. SOUTHWICK Romma
Original Assignee
Astellas Institute For Regenerative Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Institute For Regenerative Medicine filed Critical Astellas Institute For Regenerative Medicine
Publication of HK1256839A1 publication Critical patent/HK1256839A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Reproductive Health (AREA)
  • Dentistry (AREA)
HK18115924.9A 2015-08-18 2016-08-18 临床制剂 HK1256839A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562206821P 2015-08-18 2015-08-18
US62/206,821 2015-08-18
PCT/US2016/047545 WO2017031312A1 (en) 2015-08-18 2016-08-18 Clinical formulations

Publications (1)

Publication Number Publication Date
HK1256839A1 true HK1256839A1 (zh) 2019-10-04

Family

ID=56843032

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18115924.9A HK1256839A1 (zh) 2015-08-18 2016-08-18 临床制剂

Country Status (15)

Country Link
US (3) US11013808B2 (enExample)
EP (1) EP3334415A1 (enExample)
JP (3) JP7043392B2 (enExample)
KR (3) KR20230058544A (enExample)
CN (2) CN108697641A (enExample)
AU (2) AU2016308818B2 (enExample)
BR (1) BR112018003031B1 (enExample)
EA (2) EA202190722A1 (enExample)
HK (1) HK1256839A1 (enExample)
IL (3) IL299326A (enExample)
MX (2) MX2018002038A (enExample)
PH (1) PH12018500371B1 (enExample)
SG (1) SG10201913250SA (enExample)
TW (3) TW202417023A (enExample)
WO (1) WO2017031312A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9993427B2 (en) * 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
EP3674397A1 (en) 2014-12-30 2020-07-01 Cell Cure Neurosciences Ltd. Rpe cell populations and methods of generating same
CN107889507B (zh) 2015-03-23 2021-11-26 安斯泰来再生医药协会 改进的人视网膜色素(rpe)细胞和感光祖细胞的效能测定
TW202417023A (zh) * 2015-08-18 2024-05-01 美商安斯泰來再生醫藥協會 臨床調配物
JP7067744B2 (ja) * 2016-06-30 2022-05-16 株式会社ヘリオス 移植用媒体
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
AU2018393494A1 (en) * 2017-12-29 2020-07-09 Cell Cure Neurosciences Ltd. Retinal pigment epithelium cell compositions
JP2022547832A (ja) 2019-08-28 2022-11-16 アステラス インスティテュート フォー リジェネラティブ メディシン 血管疾患の処置方法
TW202122573A (zh) 2019-08-28 2021-06-16 安斯泰來再生醫藥協會 治療血管疾病之組成物及方法
IL292610A (en) 2019-10-30 2022-07-01 Astellas Inst For Regenerative Medicine Methods for producing retinal pigment epithelium cells
JP7018527B1 (ja) 2020-12-16 2022-02-10 アニコム先進医療研究所株式会社 細胞の保存方法および細胞懸濁液
CA3225810A1 (en) * 2021-07-15 2023-01-19 Joseph Piccirilli Preservative composition for nucleic acids and biological samples and methods of use
CN118871141A (zh) * 2022-03-16 2024-10-29 住友制药株式会社 移植用介质
US20250257321A1 (en) 2022-07-18 2025-08-14 Astellas Institute For Regenerative Medicine Methods of treating brain injury
EP4577642A1 (en) 2022-08-23 2025-07-02 Astellas Institute for Regenerative Medicine Photoreceptor rescue cell (prc) compositions and methods for treatment of ocular disorders
JPWO2024172043A1 (enExample) * 2023-02-14 2024-08-22
WO2025122978A1 (en) * 2023-12-06 2025-06-12 Bluerock Therapeutics Lp Cell cryopreservation and delivery vehicle and methods of using the same
FR3158635A1 (fr) * 2024-01-26 2025-08-01 Treefrog Therapeutics Composition biocompatible particulière comprenant des éléments cellulaires hétérogènes utile pour l’administration de thérapies cellulaires
FR3158633A1 (fr) * 2024-01-26 2025-08-01 Treefrog Therapeutics Composition biocompatible comprenant des éléments cellulaires hétérogènes
WO2025158056A1 (fr) * 2024-01-26 2025-07-31 Treefrog Therapeutics Composition biocompatible adaptee pour l'administration de therapies cellulaires et son utilisation notamment la maladie de parkinson
WO2025204688A1 (ja) * 2024-03-26 2025-10-02 株式会社ダイセル リン脂質膜保護用液体組成物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654266A (en) 1992-02-10 1997-08-05 Chen; Chung-Ho Composition for tissues to sustain viability and biological functions in surgery and storage
DE69227179D1 (de) * 1992-03-27 1998-11-05 Chen Chung Ho Mittel für Gewebe zur Erhaltung der Lebensfähigkeit und biologische Funktionen in der Chirurgie und Lagerung
ES2157260T3 (es) 1993-06-04 2001-08-16 Biotime Inc Solucion semejante a plasma.
IT1277707B1 (it) * 1995-12-22 1997-11-11 Chemedica Sa Formulazione oftalmica a base di ialuronato di sodio per uso nella chirurgia oculare
CN1152668C (zh) * 1997-08-22 2004-06-09 清水制药株式会社 含有葡萄糖的制剂
GB2336109A (en) 1998-04-07 1999-10-13 Univ Bristol Ophthalmic Irrigating Solution
CN1196489C (zh) * 2000-01-11 2005-04-13 欧得士株式会社 眼科手术用灌流液制剂
US7084157B2 (en) * 2002-05-17 2006-08-01 Rajeev Raut Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation
WO2005070011A2 (en) 2004-01-23 2005-08-04 Advanced Cell Technology, Inc. Improved modalities for the treatment of degenerative diseases of the retina
US20190282622A1 (en) 2004-01-23 2019-09-19 Astellas Institute For Regenerative Medicine Modalities for the treatment of degenerative diseases of the retina
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
KR102230288B1 (ko) 2006-04-14 2021-03-22 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 콜로니 형성 세포
JP2010500047A (ja) 2006-08-15 2010-01-07 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 間葉系幹細胞馴化培地
IL292561A (en) * 2007-10-12 2022-06-01 Astellas Inst For Regenerative Medicine Improved methods of rpe cell production and rpe cell preparations
WO2009137629A2 (en) 2008-05-06 2009-11-12 Advanced Cell Technology, Inc. Methods for producing enucleated erythroid cells derived from pluripotent stem cells
CN102083963A (zh) 2008-05-06 2011-06-01 先进细胞技术公司 血管瘤集落形成细胞和非移植血管瘤细胞
WO2011063005A2 (en) 2009-11-17 2011-05-26 Advanced Cell Technology, Inc. Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
CA2782013C (en) 2009-12-04 2021-06-08 Stem Cell & Regenerative Medicine International, Inc. Large scale generation of functional megakaryocytes and platelets from human embryonic stem cells under stromal-free conditions
CA3095576A1 (en) 2009-12-04 2011-06-09 Astellas Institute For Regenerative Medicine Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts
CA2806127C (en) 2010-07-23 2021-12-21 Advanced Cell Technology, Inc. Methods for detection of rare subpopulations of cells and highly purified compositions of cells
LT2780022T (lt) 2011-11-14 2019-07-10 Astellas Institute For Regenerative Medicine Žmogaus rpe ląstelių farmaciniai preparatai ir jų panaudojimas
HRP20181515T1 (hr) 2011-11-30 2018-11-16 Astellas Institute For Regenerative Medicine Mezenhimne stromalne stanice i upotreba povezana s njima
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
HRP20190460T1 (hr) 2011-12-06 2019-04-19 Astellas Institute For Regenerative Medicine Postupak proizvodnje endotelnih stanica rožnice usmjerenom diferencijacijom
CN103783031B (zh) * 2012-10-29 2015-11-18 四川新生命干细胞科技股份有限公司 一种细胞保存液
AU2013201546B2 (en) * 2012-12-18 2014-10-23 Gambro Lundia Ab Dialysis composition
CN114558032B (zh) 2012-12-21 2025-07-29 安斯泰来再生医药协会 由多能干细胞制备血小板的方法及其组合物
US20160175362A1 (en) 2014-03-14 2016-06-23 Ocata Therapeutics, Inc. Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US20160175361A1 (en) 2014-03-14 2016-06-23 Advanced Cell Technology, Inc. Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
IL307568A (en) 2013-03-15 2023-12-01 Astellas Inst For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US11241460B2 (en) 2013-03-15 2022-02-08 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US20170274019A1 (en) 2014-09-05 2017-09-28 Astellas Institute For Regenerative Medicine Retinal ganglion cells and progenitors thereof
CN107889507B (zh) 2015-03-23 2021-11-26 安斯泰来再生医药协会 改进的人视网膜色素(rpe)细胞和感光祖细胞的效能测定
TW202417023A (zh) * 2015-08-18 2024-05-01 美商安斯泰來再生醫藥協會 臨床調配物
JP2022547832A (ja) 2019-08-28 2022-11-16 アステラス インスティテュート フォー リジェネラティブ メディシン 血管疾患の処置方法
TW202122573A (zh) 2019-08-28 2021-06-16 安斯泰來再生醫藥協會 治療血管疾病之組成物及方法
IL292610A (en) 2019-10-30 2022-07-01 Astellas Inst For Regenerative Medicine Methods for producing retinal pigment epithelium cells
MX2023013079A (es) 2021-05-03 2023-11-16 Astellas Inst For Regenerative Medicine Metodos de generacion de celulas maduras del endotelio corneal.

Also Published As

Publication number Publication date
IL291163B1 (en) 2023-01-01
KR20180048722A (ko) 2018-05-10
KR20220090583A (ko) 2022-06-29
US11957754B2 (en) 2024-04-16
CA2995977A1 (en) 2017-02-23
TW202417023A (zh) 2024-05-01
US12419958B2 (en) 2025-09-23
MX2018002038A (es) 2018-07-06
EA202190722A1 (ru) 2021-10-29
JP2024074803A (ja) 2024-05-31
KR20230058544A (ko) 2023-05-03
AU2016308818A1 (en) 2018-04-05
EP3334415A1 (en) 2018-06-20
WO2017031312A1 (en) 2017-02-23
US20190030168A1 (en) 2019-01-31
US11013808B2 (en) 2021-05-25
EA037915B1 (ru) 2021-06-07
AU2022206757A1 (en) 2022-08-18
JP2018523682A (ja) 2018-08-23
IL291163B2 (en) 2023-05-01
JP2022040140A (ja) 2022-03-10
IL291163A (en) 2022-05-01
BR112018003031A2 (pt) 2018-09-18
BR112018003031B1 (pt) 2023-12-26
IL257551A (en) 2018-04-30
EA201890516A1 (ru) 2018-09-28
AU2016308818B2 (en) 2022-04-21
IL299326A (en) 2023-02-01
US20190358330A9 (en) 2019-11-28
JP7043392B2 (ja) 2022-03-29
US20240350639A1 (en) 2024-10-24
JP7449915B2 (ja) 2024-03-14
PH12018500371B1 (en) 2023-01-20
PH12018500371A1 (en) 2018-08-29
SG10201913250SA (en) 2020-03-30
TWI772270B (zh) 2022-08-01
TWI833293B (zh) 2024-02-21
CN119112939A (zh) 2024-12-13
NZ740608A (en) 2023-09-29
KR102651291B1 (ko) 2024-03-26
TW202245816A (zh) 2022-12-01
US20210275673A1 (en) 2021-09-09
TW201717912A (zh) 2017-06-01
IL257551B (en) 2022-04-01
MX2022010363A (es) 2022-09-21
CN108697641A (zh) 2018-10-23
AU2022206757B2 (en) 2024-09-05
KR102411018B1 (ko) 2022-06-20

Similar Documents

Publication Publication Date Title
HK1256839A1 (zh) 临床制剂
Cornelissen et al. Organ-specific migration of mesenchymal stromal cells: Who, when, where and why?
WO2014028493A3 (en) Exosomes and micro-ribonucleic acids for tissue regeneration
CY1123343T1 (el) Παραγωγη μιας τραπεζας μεσεγχυματικων στρωματικων κυτταρων απο τα ομαδοποιημενα μονοπυρηνα κυτταρα πολλαπλων δοτων μυελου των οστων
EP4461808A3 (en) Isolated discogenic cells, methods of using, and methods of preparing same from mammalian tissue
WO2018129368A3 (en) Methods of assessing nuclease cleavage
WO2014022423A3 (en) Hla g-modified cells and methods
WO2012048010A3 (en) Compositions of adult organ stem cells and uses thereof
MX2023000731A (es) Composiciones utiles para enzimas de internalizacion.
WO2012021845A3 (en) Improved hematopoietic stem and progenitor cell therapy
WO2014053418A3 (en) Method for obtaining mesenchymal stem cells and use thereof
WO2016201047A8 (en) Crispr/cas-related methods and compositions for improving transplantation
WO2012027514A3 (en) Compositions and methods for cardiac therapy
WO2016109840A3 (en) Compositions and methods for high efficiency in vivo genome editing
WO2016182959A8 (en) Optimized crispr/cas9 systems and methods for gene editing in stem cells
WO2016037138A8 (en) Globin gene therapy for treating hemoglobinopathies
MX2017004890A (es) Metodos y composiciones para la generación o el mantenimiento de células pluripotentes.
SG10201808258SA (en) Improved methods for manufacturing adoptive cell therapies
AU2017241807A1 (en) Medium, methods, cells and secreted factors for stem cell culture and therapy
CY1119382T1 (el) Φυσικα βλαστοκυτταρα γελης toy wharton και καθαρισμος αυτων
WO2009134532A3 (en) Homing in mesenchymal stem cells
WO2009092005A3 (en) Methods of generating cardiomyocytes and cardiac progenitors and compositions
MX2017007214A (es) Procedimiento para la expansion de linfocitos t gamma/delta.
IL287488B2 (en) Methods for the development and use of minimally polarized microaggregate cell units in tissue applications using lgr4, lgr5 and lgr6 expressing epithelial stem cells
MX377170B (es) Composiciones de gel de brimonidina y metodos de uso.